Clinical & Patient Perspective: A Treatment for Adults with Acute Hepatic Porphyria, including Acute Intermittent Porphyria (Sponsored by: Alnylam Pharmaceuticals)

  Thursday, April 4, 2024           6:30 PM - 7:30 PM ET

Description

Acute hepatic porphyria (AHP) is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. Led by Dr. Angelika Erwin, a consultant of Alnylam Pharmaceuticals, this presentation will provide a disease overview and review the clinical profile of a treatment for adults with AHP, featuring Phase 3 Study results and open-label extension data.

Attendees will also hear from an AHP patient who will share their experience with the disease and treatment.

Please join Alnylam Pharmaceuticals and Dr. Erwin to learn more about this treatment for adults with AHP. Dinner will be provided for attendees.